Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Patients with immune-mediated inflammatory disease (IMID) are at increased risk of hospitalization for heart failure (HF) when compared to the general population, reveals a study.

HF hospitalization risk greater in IMID patients

Low HDL-C levels may heighten risk of acromegaly

Individuals with low high-density lipoprotein cholesterol (HDL-C) levels face an increased risk of acromegaly, according to a large retrospective study from Korea.

Low HDL-C levels may heighten risk of acromegaly

Plant-based fasting-mimicking diet does not boost medication response in UC

The low-calorie, plant-based fasting-mimicking (LC-PB) diet does little to improve clinical response to medications in patients with active ulcerative colitis (UC), according to a study. However, LC-PB diet helps with steroid tapering and reduce serum amyloid A.

Plant-based fasting-mimicking diet does not boost medication response in UC

Linerixibat quells cholestatic itch in PBC, enabling better sleep

The ileal bile acid transporter inhibitor linerixibat provides rapid and substantial relief from cholestatic pruritus, in turn reducing associated sleep disturbances, in patients with primary biliary cholangitis (PBC), as shown in the global, phase III GLISTEN trial.

Linerixibat quells cholestatic itch in PBC, enabling better sleep

23 May 2025

Adverse events push RA-ILD patients to discontinue nintedanib

In patients with rheumatoid arthritis (RA)-related interstitial lung disease (ILD), combination therapy with disease-modifying antirheumatic drugs (DMARDs) does not negatively influence the safety and efficacy of nintedanib, reports a study. The main drivers of drug withdrawal or dose reduction in these individuals are adverse events (AEs), primarily due to comorbidities.

Adverse events push RA-ILD patients to discontinue nintedanib

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

The use of tirzepatide delivers a better safety profile when compared to other glucagon-like peptide-1 receptor agonists (GLP-1RAs), as shown by the lower risk of gastrointestinal (GI) side effects associated with its use, reports a real-world study presented at DDW 2025.

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

GLP-1RAs help reduce risk of gastrointestinal cancers

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), as opposed to insulin or metformin, provides a protective benefit against the development of gastrointestinal cancers, as shown in a study presented at DDW 2025.

GLP-1RAs help reduce risk of gastrointestinal cancers

$Can a removable boot suffice as treatment for toddler’s fracture?$

Can a removable boot suffice as treatment for toddler’s fracture?

A prefabricated, removable walking boot may be a suitable alternative to a circumferential cast for the treatment of toddler’s fracture (TF), a study suggests.

Can a removable boot suffice as treatment for toddler’s fracture?

Dostarlimab may eliminate the need for surgery in early-stage dMMR tumours

PD-1 blockade with dostarlimab may eliminate the need for surgery in patients with early-stage mismatch repair–deficient (dMMR) solid tumours amenable to curative intent surgery, a phase II trial has shown.

Dostarlimab may eliminate the need for surgery in early-stage dMMR tumours

Ageing-related diseases occur early among childhood cancer survivors

Survivors of childhood cancer undergo accelerated ageing, with a recent study showing a 2-decade earlier onset and a greater lifetime risk of common and life-threatening chronic health conditions (CHCs).

Ageing-related diseases occur early among childhood cancer survivors